Aggravated ulcerative colitis caused by intestinal Metrnl deficiency is associated with reduced autophagy in epithelial cells

Sai-long Zhang1, Zhi-yong Li1, Dong-sheng Wang1, Tian-ying Xu1, Mao-bing Fan1, Ming-he Cheng1 and Chao-yu Miao1

Metrnl is a newly identified secreted protein highly expressed in the intestinal epithelium. This study aimed to explore the role and mechanism of intestinal epithelial Metrnl in ulcerative colitis. Metrnl−/− (intestinal epithelial cell-specific Metrnl knockout) mice did not display any phenotypes of colitis under basal conditions. However, under administration of 3% dextran sodium sulfate (DSS) drinking water, colitis was more severe in Metrnl−/− mice than in WT mice, as indicated by comparisons of body weight loss, the presence of occult or gross blood per rectum, stool consistency, shrinkage in the colon, intestinal damage, and serum levels of inflammatory factors. DSS-induced colitis activated autophagy in the colon. This activation was partially inhibited by intestinal epithelial Metrnl deficiency, as indicated by a decrease in Beclin-1 and LC3-II/I and an increase in p62 in DSS-treated Metrnl−/− mice compared with WT mice. These phenomena were further confirmed by observation of autophagosomes and immunofluorescence staining for LC3 in epithelial cells. The autophagy-related AMPK-mTOR-p70S6K pathway was also activated in DSS-induced colitis, and this pathway was partially blocked by intestinal epithelial Metrnl deficiency, as indicated by a decrease in AMPK phosphorylation and an increase in p70S6K phosphorylation in DSS-treated Metrnl−/− mice compared with WT mice. Therefore, Metrnl deficiency deteriorated ulcerative colitis at least partially through inhibition of autophagy via the AMPK-mTOR-p70S6K pathway, suggesting that Metrnl is a therapeutic target for ulcerative colitis.

Keywords: Metrnl; ulcerative colitis; autophagy; AMPK-mTOR-p70S6K pathway

Acta Pharmacologica Sinica (2020) 41:763–770; https://doi.org/10.1038/s41401-019-0343-4

INTRODUCTION

Ulcerative colitis is a type of inflammatory bowel disease. In recent years, research on its etiology and pathogenesis has received extensive attention [1–3]. For the treatment of ulcerative colitis, surgery, anti-infection agents, glucocorticoids, and immunosuppressive agents are often used. However, these are symptomatic treatments, and long-term side effects are likely to cause disease recurrence [4, 5].

Autophagy is an important self-protection mechanism and is a cellular metabolic pathway that relies on lysosomes. Previous studies have shown that autophagy plays a protective role in a variety of diseases, including cancer and inflammatory and immune diseases [6–8]. In recent years, it has been reported that there is a close relationship between autophagy and inflammation, especially with certain anti-inflammatory effects [9–11]. In addition, it has been reported that activation of autophagy can ameliorate intestinal inflammation; thus, the induction of autophagy is expected to become a new strategy for the treatment of ulcerative colitis [12].

Metrnl, which is also known as Cometin or Subfatin, is a newly discovered secreted protein containing 311 amino acids with a NH2-terminal signal peptide of 45 amino acids [13]. Our previous study has shown that Metrnl is a new adipokine antagonizing insulin resistance through the PPARγ signaling pathway [14, 15]. Metrnl in adipose tissue can promote adipocyte differentiation, improve metabolism, inhibit inflammation, regulate fat function, and alleviate insulin resistance caused by obesity [13, 14, 16]. Through the examination of Metrnl expression in various tissues, we have found that Metrnl is highly expressed in both human and mouse gastrointestinal tissues, especially in intestinal epithelial cells [17]. A recent study has demonstrated that the Metrnl adipokine ameliorates spontaneous colitis in IL-10 knockout mice by attenuating mesenteric adipose tissue lesions [18]. Due to the high expression of Metrnl in intestinal epithelial cells, we speculate that intestinal epithelial Metrnl plays a role in the regulation of ulcerative colitis development.

In the present study, using a conditional knockout mouse model with a specific knockout of Metrnl in intestinal epithelial cells (Metrnl−/−/−), we explored the role of intestinal epithelial Metrnl in the development of dextran sodium sulfate (DSS)-induced colitis, an accepted experimental model of ulcerative colitis. We also examined the possible involvement of autophagy in the role of Metrnl.
MATERIALS AND METHODS

Generation of intestinal epithelial cell-specific MetnI knockout mice

All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Ethical Committee of the Second Medical University. MetnIloxP/loxP mice were generated as described elsewhere [14]. Villin-cre mice [B6. Cg-Tg(Vil1-cre)1000Gum/J; JAX stock 021504] were used to generate intestinal epithelial cell-specific MetnI knockout (Metrnl−/−) mice. The breeding strategy for MetnI mice was described elsewhere [17]. The littersmate MetnIloxP/loxP mice were used as the corresponding wild-type (WT) controls.

Cell culture and treatment

Caco-2 cells were provided by the Cell Bank of Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum. For certain groups, lipopolysaccharide (LPS) (10 ng/mL, Sigma-Aldrich, St. Louis, MO, USA) and/or chloroquine (CQ) (10 μM, Sigma-Aldrich) were administered for 12 h for stimulation.

Lentivirus-mediated knockdown of MetnI in cells

Lentiviruses encoding small hairpin RNA (shRNA) directed against human MetnI were constructed by Shanghai Bio-Link Company (Shanghai, China) and used in the present study [14]. The lentiviruses encoding scrambled shRNA were human MetnI were constructed by Shanghai Bio-Link Company (USA) and/or chloroquine (CQ) (10 μM, Sigma-Aldrich) were used in the present study [14]. The lentiviruses encoding scrambled shRNA were used to generate intestinal epithelial cell-specific MetnI knockout (Metrnl−/−) mice. The breeding strategy for MetnI mice was described elsewhere [17]. The littersmate MetnIloxP/loxP mice were used as the corresponding wild-type (WT) controls.

Immunofluorescence staining

The colon was immersed in 4% paraformaldehyde at 4 °C for 24 h, cryoprotected in 15%–30% (wt/vol) paraformaldehyde, and cut into frozen coronal slices (5-μm thickness) in cryostat (CM3050S; Leica Microsystems, Bannockburn, IL, USA). Colon sections were washed with 1 × PBS three times for 5 min each. Then, 0.2% (wt/vol) Triton X-100 and blocking serum were added successively and incubated for 15 min and 2 h, respectively. The specific primary antibodies were incubated at 4 °C overnight (Table 2). After being washed three times with 1 × PBS, the sections were incubated with the corresponding secondary antibody (Alexa Fluor 488-conjugated and Cy3-conjugated) (Jackson Immuno Research Inc., West Grove, PA, USA) for 2 h at room temperature and protected from light. Nuclei were stained with DAPI (Vector Laboratories, Burlingame, CA, USA) for 10 min. Fluorescence of colon sections was examined under a FLUOVIEW FV1000 confocal laser scanning microscope (Olympus, Japan).

Immunoblot analysis

Protein extraction and immunoblotting were performed as described previously [20]. Briefly, proteins were extracted from the tissue using a standard extraction reagent supplemented with a protease inhibitor (KANGCHEN; Shanghai, China). Protein concentrations were determined using a BCA protein assay kit (Beyotime Institute of Biotechnology; Haimen, China). Proteins were separated using SDS-PAGE, electrotransferred to nitrocellulose membranes and incubated with a primary antibody for 8–12 h at 4 °C (Table 3). The samples were then incubated with an IRDye800CW-conjugated secondary antibody (Rockland; Gilbertsville, PA, USA) for 1 h at 25 °C. Images were acquired with the Odyssey infrared imaging system (Li-Cor Bioscience; Lincoln, NE, USA). All immunoblotting experiments were repeated at least three times.

Enzyme-linked immunosorbent assay (ELISA)

Serum samples were obtained as previously described [21]. The levels of IL-1β, IL-6, and TNF-α in serum samples were quantified using commercial ELISA kits (R&D System, New York, NY, USA).

Transmission electron microscopy

Colonic tissues were separated and fixed overnight at 4 °C in 2.5% glutaraldehyde in 0.1 M PBS and then post fixed in 1% buffered osmium tetroxide for 2 h. Specimens were processed using routine procedures and examined under a transmission electron microscope (H-700; Hitachi, Tokyo, Japan).

| Table 1. Primer sets used in the study. |
|----------------------------------------|
| Genes for genotyping                  | Forward primer (5′-3′) | Reversed primer (5′-3′) |
| Floxed MetnI (MetrnIloxP/loxP)        | TGGAGGTTGAGGCTTCTGACG | GAAATGCGTTTGAGGACACGC |
| Cre (Villin-cre)                      | GCGGTCTGGCAGTAAAACTATC | GTGAACACGATTGCTGTCATT |
| Genes for real-time PCR               |                       |                       |
| MetnI                                 | CTGGAGCAGGGAGGCTTATTATTT | GGACAAACAGTCACCTGTACAG |
| GAPDH                                | GTATGACTCCACTCACGGCAA   | GGTCTGCCTCCTGGAAGATG |

| Table 2. Primary antibodies used in immunofluorescence staining. |
|---------------------------------------------------------------|
| Antibody                                   | Dilution | |
| LC3 (Novus Biologicals)                      | 1:200    | |
| CD326 (eBioscience)                         | 1:200    | |

Histological staining

Hematoxylin and eosin (H&E) staining was performed as previously described [19]. Briefly, the intestine samples used for histological analysis were fixed with 4% phosphate-buffered paraformaldehyde for 24 h and embedded in paraffin. Sections with a thickness of 4 μm were prepared and stained with H&E.
Induction of colitis in mice
An inflammatory bowel disease model was induced in WT and MetnI−/− mice with 3% or 1% DSS (molecular weight from 36,000 to 50,000 kDa, MP Biomedicals LLC, Santa Ana, CA, USA) dissolved in drinking water given ad libitum (1–10 days) as previously described [22].

Disease activity index and histological analysis in mice
Body weight, the presence of occult or gross blood per rectum, stool consistency, and colon length were determined by two investigators blinded to the treatment groups. The disease activity index was determined by combining the scores of (i) body weight loss, (ii) stool inconsistency, and (iii) blood in the stool and dividing by 3 [23]. Body weight changes are shown as a loss of baseline body weight.

Postmortem, the colon was removed, and pieces of colonic tissue were used for ex vivo analysis. For histology, rings of certain parts of the colon were fixed in 4% buffered formalin and embedded in paraffin. Sections were stained with H&E according to standard protocols. Histological scoring was performed by a pathologist in a blinded way. A focally increased number of inflammatory cells in the lamina propria was scored as 1, a confluence of inflammatory cells extending into the submucosa as 2 and a transmural extension of the infiltrate as 3. For tissue damage, discrete lymphoepithelial lesions were scored as 1, mucosal erosions as 2, and extensive mucosal damage and/or extension through deeper structures of the bowel wall as 3. Two equally weighted subscores (cell infiltration and tissue damage) were added, and the combined histological colitis severity score ranged from 0 to 6.

Statistical analysis
All data are presented as the mean ± SEM and were analyzed using Prism 6.0 software (GraphPad Software). Statistical significance was determined by a two-tailed Student’s t test. *P < 0.05 was considered statistically significant.

RESULTS
MetrnI−/− mice exhibit no phenotypes of colitis
We developed intestinal epithelial cell-specific MetnI knockout (MetrnI−/−) mice and tested the expression of MetnI in various types of tissues. The results showed that the expression of MetnI in MetnI−/− mice was almost deficient in the colon and small intestine tissues, without significant changes in other examined organs (Fig. 1a). H&E staining of colon sections showed no significant morphological differences between MetnI−/− and WT mice (Fig. 1b). To further verify whether intestinal inflammation is induced after the conditional knockout of MetnI, we performed an assay for inflammatory factors in the colon. The results showed no differences in IL-4, IL-6, and TNF-α between MetnI−/− and WT mice (Fig. 1c, d). These results indicate that colitis is not present after intestinal epithelial deficiency of MetnI alone.

Three percent DSS drinking water induces colitis on the 5th day
Before establishing the DSS-induced colitis model, to choose the optimal observation time and DSS administration concentration, we gave 3% DSS and 1% DSS drinking water to WT mice and observed the survival time of these mice at these two DSS concentrations. Fig. 2a shows that one mouse died on day 6 in the

---

[Table 3. Primary antibodies used in Western blots.]

| Antibody                      | Molecular weight (kDa) | Dilution |
|-------------------------------|------------------------|---------|
| Beclin-1 (Cell Signaling Technology) | 60                     | 1:500   |
| LC3 (Novus Biologicals)       | 14/16                  | 1:500   |
| p62 (Cell Signaling Technology) | 62                     | 1:500   |
| p-AMPK (Thr172) (Cell Signaling Technology) | 62 | 1:500 |
| AMPK (Cell Signaling Technology) | 62                     | 1:500   |
| p-mTOR (Ser 2448) (Cell Signaling Technology) | 289 | 1:500 |
| mTOR (Cell Signaling Technology) | 289                    | 1:500   |
| p-p70S6K (Ser371) (Cell Signaling Technology) | 70 | 1:500 |
| p70S6K (Cell Signaling Technology) | 70                     | 1:500   |
| GAPDH (Beyotime Biotechnology) | 36                     | 1:1000  |

---

Fig. 1 MetnIloxP/loxP Villin-cre (MetrnI−/−) mice display MetnI deficiency in the colon and small intestine and no colitis under basal conditions. a MetnI mRNA expression in various tissues. WAT white adipose tissue. n = 8. *P < 0.05. b Colon histological staining. Bar, 200 μm. c, d IL-6 and IL-4 mRNA expression and TNF-α protein levels in the colon.
3% DSS group and that all mice died after 10 days of dosing. In the
1% DSS group, no mice died during the experimental period.
There were no significant changes in body weight loss of mice in
the 1% DSS group, while the body weight of mice in the 3% DSS
group was significantly reduced on the 5th day (Fig. 2b). In
addition, the 1% DSS group showed no significant changes in
gross parameters such as disease activity index and colon length,
whereas the 3% DSS group had increased disease activity index
and shortened colon length when compared with those in the
control group (Fig. 2c, d). Histological morphology exhibited the
phenotypes of colitis with obvious tissue erosion in the 3% DSS
group (Fig. 2e). Moreover, the expression of Metrnl was
comparable between the 3% DSS and control groups. Therefore,
we selected 3% DSS and 5 days of dosing as the experimental
conditions for subsequent experiments.

Metrnl deficiency exacerbates the symptoms and colon
inflammation in DSS-induced colitis

After drinking 3% DSS water for 5 days, both WT and Metrnl−/−
mice developed severe illness characterized by the presence of
sustained weight loss, bloody diarrhea, and severe colon
inflammation, and these characteristics were associated with
hyperemia, ulceration, and bowel wall thickening leading to
further reduction in colon length. During this process, Metrnl−/−
mice showed significantly worse symptoms of weight loss, bloody diarrhea, and colon inflammation, with aggravated inflammatory infiltration in mucosa and submucosa (Fig. 3a–e). To rule out that the above differences were caused by the intake of different amounts of 3% DSS by the mice, we also measured the drinking water of the two groups of mice. The results showed no significant differences between the two groups (Fig. 3c).

Metrnl deficiency increases the expression of inflammatory factors in DSS-induced colitis.

To further verify the proinflammatory effects of Metrnl deficiency after DSS treatment, we tested inflammatory factors in mouse serum. Serum TNF-α, IL-6, and IL-1β levels remained comparable between WT and Metrnl−/− mice without DSS administration and were elevated in both groups after DSS administration. Moreover, TNF-α, IL-6, and IL-1β levels were significantly higher in DSS-treated Metrnl−/− mice than in WT mice (Fig. 4a–c). Furthermore, we investigated the levels of these inflammatory factors in the colon of Metrnl−/− and WT mice treated with DSS. TNF-α, IL-6, and IL-1β mRNA levels were significantly higher in DSS-treated Metrnl−/− mice than in WT mice (Fig. 4d–f).

Metrnl deficiency decreases the levels of autophagy induced by DSS in intestinal epithelial cells.

We examined autophagy-related proteins and found that the level of autophagy in the Metrnl−/− mice induced by 3% DSS was significantly lower than that in the WT mice. Beclin-1 and LC3-II/I expression levels decreased and p62 expression levels increased in Metrnl−/− mice induced by 3% DSS (Fig. 5a). To further verify that LC3-II was increased by enhancing the formation of autophagosomes, we measured autophagic flux by using the lysosomal inhibitor CQ. Consistent with the results from animal models, the in vitro results showed that Beclin-1 and LC3-II/I expression levels decreased and p62 expression levels increased in the Metrnl shRNA group compared with the control group under LPS treatment. Notably, CQ treatment abrogated the LPS-induced differences in autophagy levels between the Metrnl shRNA and control groups (Fig. 5b).

Further observations were obtained by transmission electron microscopy. The number of autophagosomes remained consistent between WT and Metrnl−/− mice without DSS administration and was increased in both groups after DSS administration. Moreover, the number of autophagosomes was lower in DSS-treated Metrnl−/− mice than in WT mice (Fig. 6a). To further verify the above results, we performed immunofluorescence on four groups of colon sections. The results showed that in the intestinal epithelial cell-specific marker CD326-labeled cells, the expression of LC3 in the 3% DSS-treated Metrnl−/− mice was significantly lower than that in the 3% DSS-treated WT mice (Fig. 6b).

Metrnl deficiency affects the autophagy-related AMPK-mTOR-p70S6K pathway in DSS-induced colitis.

We further examined the effects of Metrnl on autophagy-related pathways. The results showed that DSS induced an increase in p-AMPK and a decrease in mTOR and p70S6K in WT mice. These effects were significantly reduced in Metrnl−/− mice (Fig. 7), suggesting that the DSS-induced activation of the AMPK-mTOR-p70S6K pathway was partially blocked by Metrnl deficiency in the intestinal epithelium.

**DISCUSSION**

The present study demonstrates, for the first time, a protective role for Metrnl in murine DSS-induced colitis. This protection seems to be due to the regulation of Metrnl on the autophagy of intestinal epithelial cells in DSS-induced colitis. The conditional knockout of Metrnl in intestinal epithelial cells can downregulate autophagy levels in DSS-induced colitis through inhibition of the AMPK-mTOR-p70S6K pathway, thereby aggravating intestinal inflammation (Fig. 8).

Our lab screened for new adipokines in a global gene expression profiling of different adipose depots with bioinformatic methods in 2007. Metrnl was identified as a novel adipokine by our group [15]. Jorgensen et al. described Metrnl as a neurotrophic factor similar to Meteorin (Metrn) in 2012 [24]. Thus far, there are only a few studies on the function of Metrnl. Our previous study demonstrated that adipocyte Metrnl improves insulin sensitivity through the PPARγ pathway in an autocrine/paracrine manner. Jorgensen et al. [24] reported the neurotrophic activity of Metrnl in neurite outgrowth and neuroblast migration in vitro and in the survival of spiral ganglion neurons in vivo. Watanabe et al. [25] reported that Metrnl is a latent process gene for cell differentiation and neurite extension length. Rao et al. [16] showed that Metrnl could promote browning of the subcutaneous and epididymal white adipose tissue.

There is a recent report on Metrnl ameliorating Crohn’s disease, and it focused on the crosstalk of mesenteric adipose tissue and intestine. The study found that Metrnl administration attenuated mesenteric fat tissue lesions by promoting adipocyte function and differentiation partly through activating the STAT5/PPAR-γ
Fig. 5  **Autophagy is downregulated by Metnrl deficiency in vivo and in vitro.**  
**(a)** Representative Western blots and graphs showing the levels of Beclin-1, LC3-II/I, and p62 in DSS-treated Metnrl−/− mice. *n* = 8.  
**(b)** Representative Western blots and graphs showing the levels of Beclin-1, LC3-II/I, and p62 in Caco-2 cells with knockdown of Metnrl. *P* < 0.05.

Fig. 6  **Autophagy is downregulated in DSS-treated Metnrl−/− mice.**  
**(a)** Transmission electron micrograph of colon sections showing the ultrastructure of autophagosomes (red arrow). Original magnification ×12,000.  
**(b)** Representative images of immunofluorescence staining of colon sections for DAPI (blue, nuclei indicator), LC3 (red, autophagy-related protein), and CD326 (green, epithelial marker). Original magnification ×800. Bar, 50 μm.
Metrnl antagonizes ulcerative colitis
Sai-long Zhang et al.

The autophagy-related AMPK-mTOR-p70S6K pathway is impaired in DSS-treated Metrnl<sup>−/−</sup> mice. The p-AMPK/AMPK, p-mTOR/mTOR, and p-p70S6K/p70S6K ratios were determined by Western blots. n = 8. *P < 0.05.

ACKNOWLEDGEMENTS
This study was supported by grants from the National Natural Science Foundation of China (No. 81803541 and No. 81730098).

AUTHOR CONTRIBUTIONS
SLZ and ZYL performed most of the experiments and data analyses and wrote the paper. DSW, TYX, MBF, and MHC performed some experiments and data analyses. CYM designed the study, performed data analysis, and wrote and revised the paper. ADDITIONAL INFORMATION
Competing interests: The authors declare no competing interests.

REFERENCES
1. Ghosh S, Daperno M. Topical therapy in ulcerative colitis: always a bridesmaid but never a bride? Gastroenterology. 2015;148:701–4.
2. Ordas I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Br Med J. 2013;346:f432.
3. Liu CZ, Li FY, Lv XF, Ma MM, Li XY, Lin CX, et al. Endophilin A2 regulates calcium-activated chloride channel activity via selective autophagy-mediated TMEM16A degradation. Acta Pharmacol Sin. 2019;https://doi.org/10.1038/s41401-019-0298-5.
4. Ford AC, Mosayedi P, Hanauer SB. Ulcerative colitis. Br Med J. 2013;346:f432.
5. Mowat C, Cole A, Windsor A, Ahmad T, Arnott I, Driscoll R, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571–607.
6. Liu CZ, Li FY, Lv XF, Ma MM, Li XY, Lin CX, et al. Endophillin A2 regulates calcium-activated chloride channel activity via selective autophagy-mediated TMEM16A degradation. Acta Pharmacol Sin. 2019;https://doi.org/10.1038/s41401-019-0298-5. [Epub ahead of print]
7. Ding R, Wang X, Chen W, Li Z, Wei AL, Wang QB, et al. WX20120108, a novel IAP antagonist, induces tumor cell autophagy via activating ROS-FOXO pathway. Acta Pharmacol Sin. 2019;40:1466–79.
8. Yu P, Wang HY, Tian M, Li AX, Chen XS, Wang XL, et al. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in
doxorubicin-treated human melanoma cells in vitro. Acta Pharmacol Sin. 2019;40:1237–44.
9. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12:222–30.
10. Netea-Maier RT, Plantinga TS, van de Veerdonk FL, Smit JW, Netea MG. Modulation of inflammation by autophagy: consequences for human disease. Autophagy. 2016;12:245–60.
11. Shao BZ, Han BZ, Zeng YX, Su DF, Liu C. The roles of macrophage autophagy in atherosclerosis. Acta Pharmacol Sin. 2016;37:150–6.
12. Maccia-Ceja DC, Cosin-Roger J, Ortiz-Masia D, Salvador P, Hernandez C. Stimulation of autophagy prevents intestinal mucosal inflammation and ameliorates murine colitis. Br J Pharmacol. 2017;174:2501–11.
13. Zheng SL, Li ZY, Song J, Liu JM, Miao CY. Metrnl: a secreted protein with new emerging functions. Acta Pharmacol Sin. 2016;37:571–9.
14. Li ZY, Song J, Zheng SL, Fan MB, Guan YF, Qu Y, et al. Adipocyte Metrnl antagonizes insulin resistance through PPARgamma signaling. Diabetes. 2015;64:4011–22.
15. Li ZY, Zheng SL, Wang P, Xu TY, Guan YF, Zhang YJ, et al. Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression. CNS Neurosci Ther. 2014;20:344–54.
16. Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157:1279–91.
17. Li ZY, Fan MB, Zhang SL, Qu Y, Zheng SL, Song J, et al. Intestinal Metrnl released into the gut lumen acts as a local regulator for gut antimicrobial peptides. Acta Pharmacol Sin. 2016;37:1458–66.
18. Zuo L, Ge S, Ge Y, Li J, Zhu B, Zhang Z, et al. The adipokine Metrnl ameliorates chronic colitis in IL-10−/− mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis. J Crohns Colitis. 2019;13:931–41.
19. Hu G, Liu J, Zhen YZ, Xu R, Qiao Y, Wei J, et al. Rhein lysinate increases the median survival time of SAMP10 mice: protective role in the kidney. Acta Pharmacol Sin. 2013;34:515–21.
20. Wang P, Xu TY, Wei K, Guan YF, Wang X, Xu H, et al. ARR81/beta-arrestin-1 mediates neuroprotection through coordination of BECN1-dependent autophagy in cerebral ischemia. Autophagy. 2014;10:1535–48.
21. Zheng SL, Li ZY, Zhang Z, Wang DS, Xu J, Miao CY. Evaluation of two commercial enzyme-linked immunosorbent assay kits for the detection of human circulating Metrnl. Chem Pharm Bull. 2018;66:391–98.
22. Tun X, Yasukawa K, Yamada K. Involvement of nitric oxide with activation of Toll-like receptor 4 signaling in mice with dextran sodium sulfate-induced colitis. Free Radic Biol Med. 2014;74:108–17.
23. Islam MS, Kusakabe M, Horigushi K, Iino S, Nakamura T, Iwagana K, et al. PDGF and TGF-beta promote tenascin-C expression in subepithelial myofibroblasts and contribute to intestinal mucosal protection in mice. Br J Pharmacol. 2014;171:375–88.
24. Jorgensen JR, Fransson A, Fjord-Larsen L, Thompson LH, Houchnis JP, Andrade N, et al. Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo. Exp Neurol. 2012;233:172–81.
25. Watanabe K, Akimoto Y, Yugi K, Uda S, Chung J, Nakamura S, et al. Latent process genes for cell differentiation are common decoders of neurite extension length. J Cell Sci. 2012;125:2198–211.
26. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoth T, et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature. 2008;456:264–8.
27. Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, et al. A key role for autophagy and the autophagy gene Atg16L1 in mouse and human intestinal Paneth cells. Nature. 2008;456:259–63.
28. Travassos LH, Cameiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG, et al. Nod1 and Nod2 direct autophagy by recruiting ATM16L1 to the plasma membrane at the site of bacterial entry. Nat Immunol. 2010;11:55–62.
29. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, et al. Deletion of IRGM polymorphism upstream of IRGM associated with altered IRGM expression and Crohn’s disease. Nat Genet. 2008;40:1107–12.
30. Tong X, Gu J, Song R, Wang D, Sun Z, Sui C, et al. Osteoprotegerin inhibit osteoclast differentiation and bone resorption by enhancing autophagy via AMPK/mTOR/p70S6K signaling pathway in vitro. J Cell Biochem. 2019;120:1630–42.
31. Wang Z, Lai ST, Ma NY, Deng Y, Liu Y, Wei DP, et al. Radioresistnatiation of metastatic pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair. Cancer Lett. 2015;369:192–201.
32. Klionsky DJ, Abdelmohsen K, Abe A, Abedin MJ, Abeliovich H, Acevedo Arozena E, et al. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016;12:1–222.
33. Wu A, Hu P, Lin J, Xia W, Zhang R. Activating cannabinoid receptor 2 protects against diabetic cardiomyopathy through autophagy induction. Front Pharmacol. 2018;9:1292.
34. Duan P, Hu C, Quan C, Yu T, Huang W, Chen W, et al. 4-Nonylphenol induces autophagy and attenuates mTOR/p70S6K/4EBP1 signaling by modulating AMPK activation in Sertoli cells. Toxicol Lett. 2017;267:21–31.
35. Wang P, Guan YF, Du H, Zhai QW, Su DF, Miao CY. Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy. 2012;8:77–87.
36. Wang P, Shao BZ, Deng Z, Chen S, Yue Z, Miao CY. Autophagy in ischemic stroke. Prog Neurobiol. 2018;163:164-198-117.
37. Zheng H, Gong Y, Wang Z, Jiang L, Chen R, Fan X, et al. Apelin inhibits the proliferation and migration of rat PAMSCs via the activation of PI3K/Akt/mTOR signal and the inhibition of autophagy under hypoxia. J Cell Mol Med. 2014;18:542–53.